SOLICITATION NOTICE
65 -- Support Ankle products - Technical / Company Requirement Response Document
- Notice Date
- 12/2/2011
- Notice Type
- Combined Synopsis/Solicitation
- NAICS
- 339113
— Surgical Appliance and Supplies Manufacturing
- Contracting Office
- Defense Logistics Agency, DLA Acquisition Locations, DLA Troop Support - Medical, 700 Robbins Avenue, Philadelphia, Pennsylvania, 19111-5096, United States
- ZIP Code
- 19111-5096
- Solicitation Number
- ME-1105-39_Support_Ankle
- Archive Date
- 1/7/2012
- Point of Contact
- Robert Halliday, Phone: 011-49-6221-172109, Thomas Winkel, Phone: 011-49-6221-172106
- E-Mail Address
-
Robert.halliday@us.army.mil, tom.winkel@us.army.mil
(Robert.halliday@us.army.mil, tom.winkel@us.army.mil)
- Small Business Set-Aside
- N/A
- Description
- Use this document for all your responses. Fill in the attachment and provide with your initial submittal to this FBO RFIAQ. *A vendor who does not meet these requirements or who does not submit documentation to support these requirements with initial submittal will be disqualified in Phase I. *Vendor who does not meet the deadline of COB on the date/time listed in the FBO, will be disqualified from further consideration in the standardization initiative. *Please remember to attach your product literature and catalogs required in the Federal Business Opportunity. The Defense Medical Materiel Program Office (DMMPO) Medical Materiel Enterprise Standardization Office (MMESO) announces a Request for Incentive Agreement Quotation (RFIAQ) for the standardization of Support Ankle. The MMESO Europe is the lead MMESO for this project. The primary objective of this effort is to standardize the quality of care across the Military Treatment Facilities (MTFs) and operational assemblages based on the critical balance of clinical efficacy and value. The intent for this initiative is the standardization of a clinically preferred product(s) and source for institutional and operational medicine requirements at the lowest price. It is also intended for this initiative to result in the reduction of Stock Keeping Units (SKUs) and National Stock Numbers (NSN). Standardized products must be obtained through the Department of Defense (DoD) Prime Vendor (PV) Program. As an enterprise-wide clinically driven program, vendors and products must meet specific technical requirements plus products must meet or exceed specific clinical performance expectations as a primary consideration. Among vendors who meet the technical requirements and the products that meet or exceed the clinical acceptability, then clinically preferred, best value will determine selection. It is intended that the selected standardized vendor(s) for this Standardization Action (SA) support the enterprise goal of medical materiel standardization that combines operational and institutional requirements. The government is seeking a single award for this SA. The major facilities in the MMESOs North, South, West, Pacific and Europe (hereafter referred to as MMESOs) include but are not limited to MMESO North: Walter Reed National Military Medical Center, Portsmouth Naval Hospital, Womack Army Medical Center, Wright-Patterson Medical Center; MMESO South: Wilford Hall Ambulatory Surgical Center, Brooke Army Medical Center, Eisenhower Army Medical Center, Darnall Army Medical Center, Keesler Medical Center, Naval Hospital Jacksonville, Martin Army Community Hospital, Fort Benning, GA; MMESO West: Madigan Army Medical Center, William Beaumont Army Medical Center, Naval Medical Center San Diego, Irwin Army Community Hospital, Mike O'Callaghan Federal Hospital; MMESO Pacific: Tripler Army Medical Center, 18th Medical Group, Kadena AB, Okinawa, US Naval Hospital, Yokosuka, Japan; MMESO Europe: Landstuhl Regional Medical Center, Landstuhl, GE, US Naval Hospital, Naples, Italy, and 48th Medical Group, RAF Lakenheath; and Operational U.S. Forces. This SA is part of the Medical/Surgical Prime Vendor program executed by the Defense Logistics Agency (DLA) Troop Support, Directorate of Medical Materiel. To participate in this SA your company must have, or be in the process of obtaining, a Distribution and Pricing Agreement (DAPA) and a separate commercial agreement with the current Med-Surg PV for each MMESO Region, i.e., Cardinal Health, and Owens & Minor. This requirement is pursuant to the DAPA clause by which DAPA holders agree to the standardization initiative and agree to allow PVs to distribute their products. The IA resulting from this RFIAQ is a supplement to the PV Program and is not a contract. For additional information regarding DLA TS Medical's PV program please access its web site at https://www.medical.dla.mil This IA standardization initiative will be a Three Phase IPP Process: vendor (s) who meets the technical / company requirements in Phase I will be invited to advance and participate Phase II where no-charge products will be provided for clinical evaluation and Phase III where pricing will be required for submittal. Phase II and Phase III will be run concurrently. The resulting IA will be for a base period of two (2) years (24 months) from date of selection with three (3) 12-month "option" periods not to exceed a total of 5 years. Anticipated selection date is April 2012. The selection will be based on the product and vendor that provides the Best Value to the enterprise. Products and vendors that meet or exceed the technical and clinical performance requirements will be considered clinically preferred products and sources. Among vendors who meet the technical requirements and the products that meet or exceed the clinically preferred standard, best price (i.e. lowest Aggregate Post Standardization Cost) will determine selection for each MMESO AOR. Points of Contact: Mr. Robert Halliday, Clinical Analyst, Robert.halliday@us.army.mil and COM 011-49-6221-172109 or Mr. Tom Winkel, Team Leader, Tom.winkel@us.army.mil and COM 011-49-6221-172106. B. Products & Performance Required The MMESOs, are seeking product line items in the category of Support Ankle. Within the MMESOs this product line has an estimated annual dollar requirement of $979,236.34. This forecast is based on historical prime vendor sales during a recent 12-month period. Based on the recent 12-month usage data, ninety-three (93) of the total one hundred seventy-three (173) line items represent the top seven (7) products and accounts for 82.76% ($810,499.74) of the total volume in sales ($979,236.34) in the MMESOs and are clinically significant. The top high volume usage lines for this project are shown in the Technical/Company requirements below. C. Instructions to Vendors Vendors interested in participating in this standardization initiative will provide an initial response to the FBO-posted RFIAQ to Mr. Robert Halliday, Clinical Analyst, Robert.halliday@us.army.mil or Mr. Tom Winkel, Team Leader, Tom.winkel@us.army.mil. The vendor's initial responses will include detailed information requested in the technical/company criteria listed in the FBO RFIAQ and must also include: (1) Company name and address; (2) Company Point of Contact (POC) (Name and Phone Number, Fax Number, and E-mail address); and (3) Identification of the RFIAQ to which the vendor is responding. Due to the potential for e-mail to be lost in transmission, from network security, etc., vendors are strongly encouraged to confirm with the MMESO Europe that its initial submission, quote and literature actually arrived at the MMESO Europe via e-mail. Each submitting vendor is advised to confirm receipt, allowing adequate time for resubmission before the due date / time, should a problem occur with the first submission. Vendor should complete and submit the attached document. A vendor, who cannot open the attachments, may contact the POC as noted in the FBO RFIAQ and a copy will be provided via an alternate method (fax, email or hard copy). Vendors that do not meet the deadline of COB 5:00PM Eastern Standard Time (EST) on the date listed for closing, per the FBO RFIAQ, will be disqualified from further consideration in the standardization initiative. D. Source Selection Procedures The MMESO Joint Product Review Board (JPRB) will serve as the forum for clinical recommendations for product selection, seeking and evaluating opportunities for committed volume purchase agreements, and coordinating logistics efforts in support of DoD Components. The boards are chaired by Designated Senior Logisticians (DSLs) and co-chaired by Designated Senior Clinicians (DSCs) in the MMESO AORs and include clinicians and logisticians for Medical Treatment Facilities (MTFs) within each MMESO. The Clinical Advisory Committee (CAC) members are the deciding officials for this initiative. Vendor quotes should contain the vendor's best discounts off of the vendor's DAPA pricing based on committed volume of 80% of the total requirements of the MTFs in the MMESOs. The MMESO Europe reserves the right to conduct discussions and request revised quotes, if determined necessary. Technical/Company Evaluation The MMESO CPT will review the responses from the vendors and determine which vendors meet the technical/company requirements and determine acceptability. A vendor must meet the technical requirements for continued consideration in this initiative. A vendor who does not meet the requirements will be disqualified. Failure to provide any requested information or meet any of the technical requirements will disqualify the vendor from further consideration. A vendor who meets the following technical/company requirements will be qualified and invited to participate in the clinical/performance selection and will be requested to submit their best product/price discount quotes via an email communication. All communications of significant acquisition milestones (such as invitations to participate, or notices of disqualification) should be digitally signed. Technical/Company Requirements: During the acquisition planning procedures the MMESO CPT approved the company/technical requirements outlined below. The ten (10) requirements below must be answered and all supporting documentation provided with the vendor's initial submittal by the response date stated in the FBO announcement. A vendor who does not meet these requirements or who does not submit documentation to support these requirements with initial submittal will be disqualified in Phase I. 1. Vendor must provide a complete line of Support Ankle products for single use. a. This product line includes items that are latex-free/safe; constructed with different fabrics such as nylon, canvas, vinyl/nylon, canvas/elastic, knitted elastic; and having lace-up, slip-on, and/or hook/loop securement/closure devices, with padded tongues and support stays to include at a minimum the specific products listed. 1) Support ankle lace up with ankle strap or figure 8 strap size medium 2) Support ankle lace up with ankle strap or figure 8 strap size large 3) Support ankle lace up with stays size large 4) Support ankle lace up with ankle strap or figure 8 strap size small 5) Support ankle lace up with ankle strap or figure 8 strap with stays size medium 6) Support ankle lace up with stays size small 7) Support ankle hook/loop closure with stays size large b. Vendor must provide a complete itemized list of items supplied (manufactured or distributed by brands and descriptions) via excel sheet, and product catalog & literature in response to this RFIAQ. Vendors are required to supply all items listed in all sizes and styles. 2. Vendor must provide a statement confirming their products meet the industry production and safety standards set forth by the Occupational Safety and Health Administration (OSHA) North American Industry Classification System (NAICS) description for 339113 (Surgical Appliances and Supplies Manufacturing) which involves Orthopedic, Prosthetic, Surgical Appliances and Supplies used in manufacturing Support Ankle product items. 3. Vendor must provide statement revealing all products containing synthesized polymer (plastic/rubber) are clearly labeled as latex free/safe. 4. Vendor must provide documentation of what type of securement devices are used for Support Ankle. The type of securement device is not a disqualifier; however, the failure to provide supporting documentation will result in disqualification in Phase I. 5. Vendor must provide documentation of what type of lining and pad design are used for Support Ankle. The type of lining and pad design is not a disqualifier; however, the failure to provide supporting documentation will result in disqualification in Phase I. 6. Vendor must provide documentation that products are designed to be worn over or under clothing. Wearing the Support Ankle over or under clothing is not a disqualifier; however, the failure to provide supporting documentation will result in disqualification in Phase I. 7. Vendor must have a DAPA or be in the process of applying for a DAPA number for the Support Ankle. Vendor must provide the DAPA number or provide documentation the DAPA number has been applied for. 8. Vendor must have agreements with the current Med/Surg Prime Vendors for each MMESO AOR, i.e. Cardinal Health and Owens & Minor for Support Ankle, or be in the process of obtaining Prime Vendor agreements. 9. Vendor will be required to submit discounts off of DAPA for all products included in this standardization initiative when pricing is requested in Phase III. Where lower FSS prices are available, DAPA holders are required by previous agreement to provide the FSS price as the DAPA price. A vendor shall not quote FSS prices as the discounted price for purposes of this standardization initiative. A vendor who does not provide discounts off DAPA in Phase II for all products will be disqualified. 10. Vendor must indicate country from which each line item is an end product, IAW Trade Agreements Act. Vendors having existing DAPA numbers must also ensure that all DAPA line items/end products in the subject product line list the proper Trade Agreements Act country in the DAPA Management System. Phase II Clinical/Performance Evaluation Acceptability Following acceptability of the technical/company requirements, the MMESO Europe, on behalf of the CPT, will request product sample sets from the product group to be sent to the CPT members at the participating MTFs. Vendors will be given 30 calendar days from the issue of the notice in which to deliver the product samples for clinical evaluation at Phase II. Product samples must be shipped no later than fourteen (14) calendar days after issue of notice, and arrive at the designated addresses for each MTF by 5:00PM local time before the 30th calendar day. Vendor MUST be able to deliver product literature/catalog, training materials and evaluation samples to the MMESO Pacific via FedEx or UPS AND to the MMESO Europe via United States Postal Service (USPS) Express Mail AND throughout the United States by selected shipping method when requested in Phase II. Vendor must send the MMESO Europe verification regarding the shipment of literature and samples. This information will include the date of shipment, final delivery date, tracking numbers and the carrier used by the vendor. Vendor will provide only the following no cost product samples for clinical/performance evaluation. The unused samples will not be returned. One (1) each of the items per MTF listed below are to be provided as samples to each of the evaluation sites as identified in the letters of invitation. Item to Send Size Number Each to send per MTF 1. Support ankle lace up with ankle strap or figure 8 strap large 1 each 2. Support ankle lace up with ankle strap or figure 8 strap medium 1each 3. Support ankle lace up with stays large 1 each 4. Support ankle hook/loop closure with stays large 1 each 5. Support ankle lace up with ankle strap or figure 8 strap with stays medium 1 each The clinical/performance acceptability evaluation period will last for fourteen (14) calendar days. The acceptability evaluation responses will be in a Likert scale format with a one (1) through five (5) scoring range. The scale descriptors are: one (1)-Completely Unacceptable, two (2)-Overwhelmingly Unacceptable, three (3)-Partially Unacceptable, four (4)-Acceptable, and five (5)-Highly Acceptable. The MMESO JPRB has established a 4.0 as the Clinically Preferred threshold of products for standardization. A vendor scoring below the clinically preferred threshold will be disqualified from selection for this standardization initiative. A vendor scoring below the clinically preferred threshold will be disqualified from selection for this standardization initiative. Of those vendors who are qualified as clinically preferred, selection will be based on best price. A vendor who has been disqualified or has not been selected will be notified in writing upon completion of the standardization selection. Clinical /performance acceptability evaluations by the participating CPT facilities will be tabulated resulting in one score per participating MMESO per vendor. The participating MMESOs' scores by vendor will then be combined resulting in one final vendor performance evaluation score. All clinical/performance acceptability evaluations will be tabulated by the MMESO Europe and results will be forwarded to the MMESO CPT for final review. There will be approximately thirteen (13) MTFs enterprise wide that will be evaluating products. Clinical/Performance Requirements: During the acquisition planning procedures the MMESO CPT approved the clinical/performance requirements outlined below: 1. NAICS 339113-Patient Comfort - Product is lightweight. The ankle support must be lightweight in order to provide patient comfort due to the duration the device may need to be applied. 2. NAICS 339113-Proper Fit and Patient Safety - The product has adjustable securement devices. The ankle support must have securement devices that allow for proper fit and reduced migration resistance to stabilize the injured or diseased lower extremity body part. 3. NAICS 339113-Patient Comfort - Product has features to provide comfort and stability to the injured/diseased body part. The ankle support must have padding that contours to the injured or diseased lower body part providing support and stabilization necessary for healing. Price Analysis Upon completion of the Phase I - Technical/Company Requirements, a vendor who is found technically acceptable will be qualified / invited to provide product samples and price discount quotes concurrently. A vendor will be given 30 calendar days from the date of pricing requests to submit IA pricing quotes in a prescribed electronic spreadsheet format, based upon the requirements of the MMESOs. Pricing will be submitted to MMESO Europe and must be received by 5:00 PM EST, thirty (30) calendar days after the issue date of the vendor notice to submit best price quotes. Vendor quotes should contain the vendor's best product matches for the specific products requested in this announcement. Vendor quotes should contain the vendor's best discounts off of the vendor's DAPA pricing for the products identified in this announcement (based on committed volume of 80% of the total requirements of the MTFs in the MMESOs). Price will be analyzed based on the projected Aggregate Post-Standardization costs for each vendor. Aggregate Post-Standardization Cost will be calculated for each vendor by applying the vendor's offered prices to the anticipated annual usage of the enterprise. Unmatched items will be represented in the Post-Standardization Cost at a baseline non-discounted price (current DAPA price of product with highest procurement). Among the products and sources that were determined to be clinically preferred, the best price Aggregate Post-Standardization Cost will be selected.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/DLA/J3/DSCP-M/ME-1105-39_Support_Ankle/listing.html)
- Place of Performance
- Address: ERMC HQ, CMR 442, Dept G4, Bldg 3613, Rm 0055, Heidelberg,Nachrichten Kaserne,, Non-U.S., APOAE09042, Germany
- Record
- SN02632975-W 20111204/111202234653-dfe82a6aa1859ffb91a1076831142f30 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |